New product newswire: January 8, 2007
Verdeso (desonide) Foam, 0.05%, has been FDA-approved for the treatment of mild to moderate atopic dermatitis (eczema) in adults and children as young as three months of age. The low-potency topical steroid is the product of Connetics Corp., Palo Alto, Calif., (650) 843-2800.
RX
NEW DRUGS
Verdeso (desonide) Foam, 0.05%, has been FDA-approved for the treatment of mild to moderate atopic dermatitis (eczema) in adults and children as young as three months of age. The low-potency topical steroid is the product of Connetics Corp., Palo Alto, Calif., (650) 843-2800.
NEW INDICATIONS
Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn., (203) 798-9988, has received FDA approval for a new indication for Mirapex (pramipexole dihydrochloride) Tablets. Approved earlier for the treatment of idiopathic Parkinson's disease, Mirapex can now be used for the treatment of moderate to severe primary restless leg syndrome.
NEW FORMULATIONS
NOW AVAILABLE
Takeda Pharmaceuticals, Lincolnshire, Ill., (847) 383-3000, reported that duetact (pioglitazone HCl and glimepiride) is now available in pharmacies nationwide. Indicated for the treatment of Type 2 diabetes, it combines two commonly used diabetes medications in a single tablet. It is taken once daily and is available in strengths of 30 mg/2 mg and 30 mg/4 mg.
